Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-383 vs Co-administration of Lobeglitazone, Empagliflozin, and Metformin in Healthy Subjects
NCT06483243Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone + empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Started Apr 2024; status: completed.
02
Drugs
lobeglitazone + empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06483243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483243.